Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Well-known examples of these drugs are those that perturb the formation of the mitotic spindle such as taxanes and vinca alkaloids”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315 · cited 1×
“Once proper chromosome alignment is established, cyclin B and securin are degraded by the anaphase-promoting complex/cyclosome bound to CDC20 (APC/C CDC20”
BackgroundTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216 · cited 1×
“Oncogenic activity Overexpression of aurora kinase A induces oncogenic transformation in immortalized rodent fibroblast”
BackgroundDitchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundHauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., & Peters, J.-M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208092 · Cited by 1,155 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“Most recently, tumour cell lines carrying a KRAS-G13D mutation were shown to be hypersensitive to inhibition of PLK1 (Ref”
Background
Cited by
Items 301–400 of 609
Mio depletion links mTOR regulation to Aurora A and Plk1 activation at mitotic centrosomes
Platani, M., Trinkle‐Mulcahy, L., Porter, M., Jeyaprakash, A. A., & Earnshaw, W. C. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201410001 · Cited by 28
“Both of these mitotic kinases have numerous important roles in spindle formation and centrosome separation (Lens et al., 2010).”
BackgroundKawai, M., Nakashima, A., Kamada, S., & Kikkawa, U. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0150-2 · Cited by 23
“Aurora kinases A and B are found in various tissues, but the expression of Aurora kinase C is restricted in testis and its overexpression has been reported in certain cancer cells [15].”
BackgroundInfluentialAurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL
Mazzera, L., Lombardi, G., Abeltino, M., Ricca, M., Donofrío, G., Giuliani, N., Cantoni, A. M., Corradi, A., Bonati, A., & Lunghi, P. (2013) · Blood · doi:10.1182/blood-2013-02-482356 · Cited by 24
D’Avino, P. P., & Capalbo, L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00221 · Cited by 27
“However, in the long term, Aurora B inhibitors also interfere with the division of normal cells and indeed clinical toxicity profiles ofAurora inhibitors indicated frequent side effects such as myelosuppression, febrile neutropenia, and gastrointestinal problems (nausea, diarrhea, and mucositis), some of which have be…”
BackgroundInfluentialHypoxia‐induced alterations of G2 checkpoint regulators
Hasvold, G., Lund‐Andersen, C., Lando, M., Patzke, S., Hauge, S., Suo, Z., Lyng, H., & Syljuåsen, R. G. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.015 · Cited by 24
Phospho-Pon Binding-Mediated Fine-Tuning of Plk1 Activity
Zhu, K., Shan, Z., Zhang, L., & Wen, W. (2016) · Structure · doi:10.1016/j.str.2016.04.012 · Cited by 23
Cortes, J. E., Podoltsev, N. A., Kantarjian, H. M., Borthakur, G. M., Zeidan, A. M., Stahl, M. F., Taube, T., Fagan, N. M., Rajeswari, S., & Uy, G. L. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02994-8 · Cited by 24
Bioorthogonal Imaging of Aurora Kinase A in Live Cells
Yang, K. S., Budin, G., Reiner, T., Vinegoni, C., & Weissleder, R. (2012) · Angewandte Chemie · doi:10.1002/ange.201200994 · Cited by 23
Zhu, H., Li, Q., Zhao, Y., Peng, H., Guo, L., Zhu, J., Jiang, Z., Zeng, Z., Xu, B., & Chen, S. (2021) · Oncogene · doi:10.1038/s41388-021-01893-4 · Cited by 22
Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit
Dall, G., Hamilton, A. L., Ratnayake, G., Scott, C. L., & Barker, H. E. (2022) · Cancers · doi:10.3390/cancers14061561 · Cited by 26
A SUMOylation motif in Aurora-A: implications for spindle dynamics and oncogenesis
de Castro, I. P. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00050 · Cited by 24
“All these results have aroused interest in Aurora-A as a putative oncogene and as an attractive anti-tumoral therapeutic target (Katayama et al., 2003; Perez De Castro et al., 2008; Lens et al., 2010).”
BackgroundMashima, T., Ushijima, M., Matsuura, M., Tsukahara, S., Kunimasa, K., Furuno, A., Saito, S., Kitamura, M., Soma‐Nagae, T., Seimiya, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12682 · Cited by 22
Falkenthal, T. E. H., Nymoen, D. A., Holth, A., Brusegard, K., Flørenes, V. A., Kærn, J., Trope, C. G., & Davidson, B. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.08.002 · Cited by 22
Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor
Alimova, I. N., Pierce, A. M., Harris, P. S., Donson, A. M., Birks, D. K., Prince, E. W., Balakrishnan, I., Foreman, N. K., Kool, M., Hoffman, L. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21932 · Cited by 22
“PLK1 is essential for DNA damage response, cell cycle division, and spindle formation [8].”
BackgroundTPX2 promotes cell proliferation and migration via PLK1 in OC
Ma, S., Rong, X., Gao, F., Yang, Y., & Wei, L. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171056 · Cited by 25
“Of the five known human PLKs, PLK1 is the most extensively studied because of its crucial role in cell-cycle regulation [33].”
PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDTX models
Dang, S.-C., Fan, Y., Cui, L., Chen, J., Qu, J.-G., & Gu, M. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s169880 · Cited by 22
“genome stability in mitosis, spindle assembly, and DNA damage response.(15,16) Previous studies have shown that overexpressed PLK1 is associated with poor survival rate in a variety of cancers including breast, melanoma, and non-small cell lung, suggesting PLK1 may be a promising therapeutic target for cancer manageme…”
BackgroundRetractedAromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors
Sun, J., Lv, P., Guo, F., Wang, X., Han, X., Zhang, Y., Sheng, G.-H., Qian, S., & Zhu, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.026 · Cited by 22
Ctortecka, C., Palve, V. C., Kuenzi, B. M., Fang, B., Sumi, N. J., Izumi, V., Novakova, S., Kinose, F., Rix, L. L. R., Haura, E. B., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000713 · Cited by 25
Kabisch, M., Bermejo, J. L., Dünnebier, T., Ying, S., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Shah, M., Perkins, B., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu326 · Cited by 21
“Indeed, high expression levels of INCENP were observed in colorectal cancer cell lines (22), whereas high expression levels of survivin (23) and AURKB (24,25) have been found in various cancers including breast cancer and shown to be associated with poor prognosis (26,27).”
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl, M. F., Lu, B. Y., Kim, T. K., & Zeidan, A. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0503-8 · Cited by 22
“Theaurorakinasesareimportantmitoticregulators,playingcritical roles inchromosomealignment,segregation,andcytokinesis [78].”
Chi, Y., Yeh, T., Ke, Y., Lin, W., Tsai, C., Wang, W.-P., Chen, Y., Su, Y., Wang, P., Chen, Y.-F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01806 · Cited by 21
Du, X., Qi, H., Ji, W., Li, P., Hua, R., Wen-liang, H., & Qi, F. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/9408839 · Cited by 27
Fisher, L. A., Wang, L., Wu, L., & Peng, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572149 · Cited by 23
“Disrupting the function of these kinases leads to various defects in mitotic progression (4).”
Zou, J., Tian, F., Li, J., Pickner, W. J., Long, M., Rezvani, K. S., Wang, H., & Zhang, D. (2013) · Biology Open · doi:10.1242/bio.20135801 · Cited by 22
“PLK1 is a canonical serine/threonine kinase and belongs to the family of polo-like kinases (Archambault and Glover, 2009; de Cárcer et al., 2011; Lens et al., 2010; Strebhardt, 2010).”
Liu, X., Zheng, H., & Qu, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1495 · Cited by 23
“This is likely the result of decreased PLK1 activity because of the well recognized extensive interplay between PLK1 and Aurora B kinases (5).”
BackgroundAurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
Wu, J., Cheng, Z., Xu, X., Fu, J., Wang, K., Liu, T., Wu, C., Kong, X., Yang, Q., Yan, G., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00422 · Cited by 21
Elimination of HER3‑expressing breast cancer cells using aptamer‑siRNA chimeras
Nachreiner, I., Hussain, A. F., Wüllner, U., Machuy, N., Meyer, T. F., Fischer, R., Gattenlรถhner, S., Meinhold-Heerlein, I. M., Barth, S., & Tur, M. K. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7753 · Cited by 25
“ized member of the human PLK family, which plays a pivotal role in mitotic entry, spindle assembly, and DNA damage response (11).”
BackgroundSubramaniyan, B., Jagadeesan, K., Ramakrishnan, S., & Ganeshan, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.027 · Cited by 21
Wang, Y., Duo, D., Yan, Y., He, R., & Wu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110560 · Cited by 23
Inhibition of Aurora Kinase B activity disrupts development and differentiation of salivary glands
Shaalan, A., Teshima, T. H. N., Tucker, A. S., & Proctor, G. (2021) · Cell Death Discovery · doi:10.1038/s41420-020-00393-w · Cited by 20
Zuco, V., Cesare, M. D., Zaffaroni, N., Lanzi, C., & Cassinelli, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3538 · Cited by 21
“Indeed, depletion of PLK1 gene expression results in inhibition of proliferation due to accumulation in the mitotic phase and apoptosis induction in tumor cell lines [7, 8].”
BackgroundInfluentialMitotic Failures in Cancer: Aurora B Kinase and its Potential Role in the Development of Aneuploidy
Hegyi, K., & Méhes, G. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9534-8 · Cited by 21
Jantscher, F., Pirker, C., Mayer, C., Berger, W., & Sutterlüty, H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-28 · Cited by 20
Tan, Q., Chen, F., Zhuo, X., Guo, X., Yun, T., Liu, Y., Zhang, C., & Lai, L. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00261 · Cited by 20
Lu, Y., Wang, P., Wang, J., Ronald, C. W., & Lee, S. C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27813 · Cited by 21
Helen, S., Kishikova, L., Powell, F., Wheatley, S. P., & Chevassut, T. J. T. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.12.006 · Cited by 20
“However, both kinases have different effects on the mitotic process [18].”
InfluentialRinger, L., Sirajuddin, P., Heckler, M. M., Ghosh, A. K., Suprynowicz, F. A., Yenugonda, V. M., Brown, M. L., Toretsky, J. A., Üren, A., Lee, Y., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17682 · Cited by 20
“The Aurora-family of kinases is comprised of three genes (aurka, aurkb and aurkc) and Aurora Kinase A localizes to the centrosomes and spindle poles and regulates spindle assembly and centrosome maturation.(18) Aurora Kinase B acts in part to correct for misaligned chromosomes during mitosis,(19) and histone H3 that h…”
BackgroundHe, S., Feng, M., Liu, M., Yang, S., Yan, S., Zhang, W., Wang, Z., Hu, C., Xu, Q., Chen, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113989 · Cited by 20
“There have been extensive studies revealing that Aurora-A is also an important oncogene with frequent amplification and/or overexpression in multiple cancers [2].”
BackgroundTsai, A.-C., Wang, C.-Y., Liou, J.-P., Pai, H.-C., Hsiao, C.-J., Chang, J.-Y., Wang, J.-C., Teng, C.-M., & Pan, S.-L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.128 · Cited by 19
“Aurora kinase A and B are required for centrosome separation, mitotic spindle assembly, chromosome biorientation, and cytokinesis during mitosis.(34,35) Our”
BackgroundFurukawa, T., Tanji, E., Kuboki, Y., Hatori, T., Yamamoto, M., Shimizu, K., Shibata, N., & Shiratori, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-88 · Cited by 20
“AURKB encodes aurora kinase B (AURKB), which is involved in chromosome segregation and cytokinesis during mitosis [14].”
Zheng, Y., & Murphy, L. C. (2016) · Nuclear Receptor Signaling · doi:10.1621/nrs.14001 · Cited by 22
“It functions mainly in centrosome separation and spindle formation, but may also have roles in chromosome alignment and chromosome segregation during mitosis [Lens et al., 2010].”
BackgroundZNF300 promotes chemoresistance and aggressive behaviour in non‐small‐cell lung cancer
Yu, S., Ao, Z., Wu, Y. M., Song, L., Zhang, P., Li, X., Liu, M., Qian, P., Zhang, R., Li, X., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12924 · Cited by 19
Han, T.-L., Sha, H., Ji, J., Li, Y., Wu, D.-S., Hu, L. T., Hu, B., & Jiang, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-81563-3 · Cited by 23
Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Li, Y., Li, Z., & Zhu, W. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170921101947 · Cited by 21
Targeting the CINful genome: Strategies to overcome tumor heterogeneity
Cunningham, C. E., MacAuley, M. J., Yadav, G., Vizeacoumar, F. S., Freywald, A., & Vizeacoumar, F. J. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.02.006 · Cited by 21
Li, H., Hu, P., Wang, Z., Wang, H., Yu, X., Wang, X., Qing, Y., Zhu, M., Xu, J., Li, Z., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02623-2 · Cited by 19
“In addition, it is well known that Plks plays a fundamental role in cell division and its inhibition leads to a failure in completing mitosis, and Aurora kinases are involved in centrosome function and mitotic spindle assembly, participate in the kinetochore complex, and favor cytokinesis (Lens et al. 2010).”
BackgroundWhen Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases
Boi, D., Rubini, E., Breccia, S., Guarguaglini, G., & Paiardini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054746 · Cited by 22
“Aurora-A is frequently overexpressed or amplified in a variety of solid and hematologic (blood-related) tumours [89,97], and according to the Cancer Genome Atlas (TCGA), it is overexpressed in almost 88% of the tumours observed [98].”
BackgroundTPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
Guenther, M., Surendran, S. A., Haas, M., Heinemann, V., von Bergwelt‐Baildon, M., Engel, J., Werner, J., Boeck, S. H., & Ormanns, S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02295-x · Cited by 18
“One potential mechanism by which TPX2 may mediate gemcitabine resistance is through its control over aurora kinase A (AURKA) [8], which is strongly linked to Polo-like-kinase-1 (PLK1) activity [27, 28].”
BackgroundCell cycle inhibitors for the treatment of NSCLC
Shcherba, M., Liang, Y., Fernandes, D. L., Perez-Soler, R., & Cheng, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.902935 · Cited by 19
“A wave of aurora kinase inhibitors have been developed, including pan and selective inhibitors [19,71].”
BackgroundLi, C., Zhou, X., Wang, Y., Jing, S., Yang, C., Sun, G., Liu, Q., Cheng, Y., & Wang, L. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2416 · Cited by 18
Cell Cycle Control: A System of Interlinking Oscillators
Poon, R. Y. C. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1538-6_1 · Cited by 18
Dittrich, C., Fridrik, M., Koenigsberg, R. A., Lee, C., Goeldner, R.-G., Hilbert, J., & Greil, R. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0201-7 · Cited by 18
“This limitation is not even restricted to the entire family of Aurora kinase inhibitors but can be identified as a general feature of all inhibitors targeting the process of mitosis, including kinesins, and polo-like kinases [43–45].”
Phosphorylation of DEPDC1 at Ser110 is required to maintain centrosome organization during mitosis
Chen, D., Ito, S., Hyodo, T., Asano‐Inami, E., Yuan, H., & Senga, T. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.06.005 · Cited by 18
“For example, mitotic kinases, such as Aurora and PLK1, are overexpressed in multiple cancers, and inhibitors for these kinases have been extensively developed for possible cancer treatment [13,14].”
BackgroundDNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives
Geyik, Ö. G., Anichini, G., Ulukaya, E., Marra, F., & Raggi, C. (2022) · Cells · doi:10.3390/cells11091463 · Cited by 19
Development of MPS1 Inhibitors: Recent Advances and Perspectives
Zeng, Y., Ren, X., Jin, P., Zhang, Y., Zhuo, M., & Wang, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00963 · Cited by 19
Jayanthan, A., Ruan, Y., Truong, T. H., & Narendran, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102741 · Cited by 18
“It has been well established that cell cycle protein kinases are overexpressed and exhibit aberrant activity in several malignancies, resulting in uncontrolled proliferation [8–10].”
BackgroundCaruso, M., Valsasina, B., Ballinari, D., Bertrand, J. A., Brasca, M. G., Caldarelli, M., Cappella, P., Fiorentini, F., Gianellini, L. M., Scolaro, A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.065 · Cited by 17
Kiryanov, A. A., Natala, S. R., Jones, B., McBride, C. M., Feher, V. A., Lam, B., Liu, Y., Honda, K., Uchiyama, N., Kawamoto, T., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.009 · Cited by 17
Zhang, Y., Wu, Z., Liu, D., Wang, M., Xiao, G., Wang, P., Sun, X., Ren, H., Tang, S., & Du, N. (2017) · Oncotarget · doi:10.18632/oncotarget.17301 · Cited by 17
“Polo-like kinase 1(PLK1), the best-characterized member of polo-like kinase family, plays a crucial role in cell-cycle regulation via maintaining genome stability [7].”
BackgroundDiscovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents
Qi, B., Zhong, L., He, J., Zhang, H., Li, F., Wang, T., Zou, J., Lin, Y., Zhang, C., Guo, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00353 · Cited by 17
Zhu, Y., Liu, Z., Qu, Y., Zeng, J., Yang, M., Li, X., Wang, Z., Su, J., Wang, X., Yu, L., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04098-w · Cited by 17
A review of Plks: Thinking outside the (polo) box
Korns, J., Liu, X., & Takiar, V. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23388 · Cited by 17
Aurora kinase A is essential for correct chromosome segregation in mouse zygote
Kovaříková, V., Burkuš, J., Rehák, P., Brzáková, A., Solc, P., & Baran, V. (2015) · Zygote · doi:10.1017/s0967199415000222 · Cited by 17
“Conversely, mitotic arrest induced by inhibition of PLK1 is abrogated on inhibition of Aurora B function (for review see Lens et al., 2010).”
BackgroundCarmena, M., Ortiz-Lombardı́a, M., Ogawa, H., & Earnshaw, W. C. (2014) · Open Biology · doi:10.1098/rsob.140162 · Cited by 18
Lee, H., Min, S., Jung, Y., Chae, S., Heo, J., Lee, J., Kim, T. S., Kang, H. C., Nakanish, M., Cha, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26220-z · Cited by 17
Lin, Y.-C., Chen, Y.-N., Lin, K.-F., Ff, W., Chou, T.-Y., & Chen, M.-Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.527 · Cited by 16
Nakamura, K., Aihara, K., & Ishida, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-01016 · Cited by 20
Mitotic Kinases and p53 Signaling
Ha, G., & Breuer, E.-K. Y. (2012) · Biochemistry Research International · doi:10.1155/2012/195903 · Cited by 21
“Studies indicate that Aurora kinases and Plks are mainly involved in regulating the centrosome cycle and mitotic spindle formation, while Mps1, Bub1, and BubR1 regulate the spindle assembly checkpoint [34, 35].”
HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis
Monteonofrio, L., Valente, D., Ferrara, M., Camerini, S., Miscione, R., Crescenzi, M., Rinaldo, C., & Soddu, S. (2018) · Oncogene · doi:10.1038/s41388-018-0191-6 · Cited by 16
“However, proliferating normal cells are also significantly affected resulting in meaningful clinical toxicity [53].”
BackgroundExpression profile‑driven discovery of AURKA as a treatment target for liposarcoma
Yen, C., Chen, S., Hung, G., Wu, P., Chua, W., Lin, Y., Yen, C., Chen, Y., Wang, J., Yang, M., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4861 · Cited by 16
“Among the 12 overlapping genes, AURKA is a well-known gene involved in cell cycle regulation (26).”
BackgroundVolasertib for AML: clinical use and patient consideration
Hao, Z., & Kota, V. K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s60762 · Cited by 21
Liu, L.-Y., Huang, W., Lin, R.-J., Lin, S.-Y., & Liang, Y. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400271n · Cited by 16
Deng, Z., Chen, G., Liu, S., Li, Y., Zhong, J., Zhang, B., Li, L., Huang, H., Wang, Z., Xu, Q., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112697 · Cited by 16
Torén, W., Ansari, D., & Andersson, R. E. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0715-8 · Cited by 15
Jiang, S., Li, W., Zhang, Y., Lin, J., & Huang, P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113594 · Cited by 21
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Xu, C., Liu, Y., & Zhao, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210831142311 · Cited by 16
Poonperm, R., Takata, H., Uchiyama, S., & Fukui, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183298 · Cited by 16
Huang, Y., Huang, S., Ma, L., Wang, Y., Wang, X., Xiao, L., Qin, W., Li, L., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723293 · Cited by 15
“PKL1 is a key regulator for the cell cycle progression, themain function of PLK1 is to control mitotic entry and maintain genomic stability in mitosis and DNA damage response (44).”
BackgroundENMD-2076 for hematological malignancies
How, J., & Yee, K. W. L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668882 · Cited by 14
“Inhibition of Aurora B activity, either alone or in conjunction with inhibition of Aurora A kinase activity, leads to progression through mitosis and failure of cytokinesis with polyploidal cells, which eventually results in apoptosis in vitro [11,21].”
BackgroundLi, Y., Zhou, W., Tang, K., Chen, X., Feng, Z., & Chen, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5908 · Cited by 15
“Aurora kinase has been observed highly expressed and amplified in breast cancer, which is related to survival and tumorigenesis (6,7).”
BackgroundPayton, M. N., Cheung, H.-K., Ninniri, M. S. S., Marinaccio, C., Wayne, W. C., Hanestad, K., Crispino, J. D., Juan, G., & Coxon, A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0186 · Cited by 14
Goroshchuk, O., Vidarsdóttir, L., Björklund, A.-C., Hamil, A. S., Kolosenko, I., Dowdy, S. F., & Palm‐Apergi, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59653-5 · Cited by 15
Phosphorylation of PLK3 Is Controlled by Protein Phosphatase 6
Aquino-Perez, C., Palek, M., Stolařová, L., von Morgen, P., & Macůrek, L. (2020) · Cells · doi:10.3390/cells9061506 · Cited by 15
“In vertebrates, Polo-like kinase family comprises of five members including PLK1 that is essential for formation of a bipolar mitotic spindle and for cytokinesis [3,4]; PLK2 and PLK4 that are involved in centriole biogenesis and duplication [5]; and PLK5 that lacks the kinase activity and plays a structural role in ne…”
BackgroundThe Widely Used Antihelmintic Drug Albendazole is a Potent Inducer of Loss of Heterozygosity
Castro, L. S. E. P. W., Pieters, W., Alemdehy, M. F., Aslam, M. A., Buoninfante, O. A., Raaijmakers, J. A., Pilzecker, B., van den Berk, P. C. M., Riele, H. T., Medema, R. H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.596535 · Cited by 14
“Inhibition of mitotic proteins like polo-like kinase 1 (PLK1), Aurora kinase A (AURKA) and Aurora kinase B (AURKB) leads to chromosome segregation errors, aneuploidy, polyploidy and micronuclei formation (Lens et al., 2010).”
BackgroundSelf-citationPLK1 Mitigates Intervertebral Disc Degeneration by Delaying Senescence of Nucleus Pulposus Cells
Zhang, Z., Huang, Y., Xu, N., Wang, J., Yao, T., Xu, Y., Qiao, D., Gao, J., Shen, S., & Ma, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.819262 · Cited by 14
Ajeawung, N. F., Faure, R. L., Jones, C., & Kamnasaran, D. (2013) · Future Oncology · doi:10.2217/fon.13.73 · Cited by 15
“Bpv(pic) functions by decreasing the expression of the microtubule associated proteins PLK1 and AURKA, which regulate mitotic entry, spindle formation, centrosome separation and cytokinesis [62]; findings that collectively assert that an inhibition of CDC25 is anticipated to have profound consequences on mitosis.”
BackgroundTargeted therapy of acute myeloid leukemia
Carneiro, B. A., Altman, J. K., Kaplan, J. B., Ossenkoppele, G. J., Swords, R. T., Platanias, L. C., & Giles, F. J. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1004316 · Cited by 14
“Polo-like kinases (Plk 1–5) are mitotic serine/threonine kinases involved in cell cycle regulation in the G2/M phase [117,118].”
BackgroundA requirement of Polo-like kinase 1 in murine embryonic myogenesis and adult muscle regeneration
Jia, Z., Nie, Y., Yue, F., Kong, Y., Gu, L., Gavin, T. P., Liu, X., & Kuang, S. (2019) · eLife · doi:10.7554/elife.47097 · Cited by 16
“effect in vitro and in vivo, providing strong preclinical and clinical support for the use of PLK1 inhibitors in cancer therapy (Degenhardt and Lampkin, 2010; Lens et al., 2010).”
BackgroundLiu, Q., Zhang, X., Tang, H., Liu, J., Fu, C. S., Sun, M., Zhao, L., Wei, M., Yu, Z., & Wang, P. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00740-y · Cited by 14
Ye, F., Shi, C., Wang, D., Wang, X., & Chen, Z. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2019.0149 · Cited by 16
“DSN1 is a conserved kinetochore protein and it has a key role in chromosome-spindle attachment that is a biological process of mitosis (Lens et al., 2010).”
Zhang, X., Hagen, J., Muniz, V. P., Smith, T. J., Coombs, G. S., Eischen, C. M., Mackie, D. I., Roman, D. L., Rheeden, R. V. V., Darbro, B. W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080228 · Cited by 15
“Aurora B expression is highest in M phase [36] and its altered expression (elevated or reduced) causes failed cytokinesis, centrosome amplification and multinucleation [37].”
BackgroundChang, C., Yeh, T., Chen, C., Wang, W.-P., Chen, Y.-T., Tsai, C., Chen, Y.-F., Ke, Y., Wang, J.-Y., Chen, C.-P., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0602 · Cited by 13
Matada, G. S. P., Abbas, N., Dhiwar, P. S., Singh, E., Ghara, A., & Das, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2004236 · Cited by 13
“Aurora-A and Aurora-B have been found to be overexpressed in many human cancers (Carmena & Earnshaw, 2003; Giet & Prigent, 1999; Lens et al., 2010) such as primary colorectal carcinoma, gliomas, breast, ovarian, and pancreatic cancers (Bernard et al., 1998; Gritsko et al., 2003; Kimura et al.,…”
BackgroundCen, S., Peng, X., Deng, J., JIN, H., Deng, Z., LIN, X., Zhu, D., Jin, M. L., Zhu, Y., Zhang, P., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028256 · Cited by 14
“PLK1 is mainly involved in the G1/M transition of cell cycle division by regulating centrosome maturation, disjunction and microtubule attachment [30].”
BackgroundSimultaneous PLK1 inhibition improves local tumour control after fractionated irradiation
Krause, M., Kummer, B., Deparade, A., Eicheler, W., Pfitzmann, D., Yaromina, A., Kunz‐Schughart, L. A., & Baumann, M. A. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.038 · Cited by 13
“PLK1 plays an important role in mitotic progression, while PLK1 inhibition results in mitotic arrest and death of many cells due to mitotic catastrophe [20,33].”
BackgroundBeussel, S., Hasenburg, A., Bogatyreva, L., Hauschke, D., Werner, M., & Laßmann, S. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200212 · Cited by 13
“expression Aurora-A and Aurora-B are central kinases in cell division and cell proliferation, albeit with different dynamics and functions.(19) To test whether Aurora-A and Aurora-B protein expression is correlated in ovarian carcinomas, Aurora-A (data from Lassmann et al(27)) and Aurora-B protein expression were corr…”
BackgroundCell cycle protein Bora serves as a novel poor prognostic factor in multiple adenocarcinomas
Zhang, Q.-X., Gao, R. C., Xiang, J., Yuan, Z.-Y., Qian, Y.-M., Yan, M., Wang, Z.-F., Liu, Q., Zhao, H.-D., & Liu, C.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.16631 · Cited by 13
“Recently, a large number of inhibitors for Aurora A and Plk1 kinases are being evaluated as anticancer drugs in Phase I or Phase II clinical trials, such as Aurora A kinase inhibitors: MLN8054 (Phase I), MLN8237 (Phase II), ENMD-2076 (Phase II), MP529 (preclinical) and Plk1 inhibitors: BI2536 (Phase II), BI6727 (Phase…”
BackgroundLi, Z., Cui, Q., Xu, J. C., Cheng, D., Wang, X., Li, B., Lee, J. M., Xia, Q., Kusakabe, T., & Zhao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-15884-7 · Cited by 13
Targeting the centrosome and polo-like kinase 4 in osteosarcoma
Kelleher, F. C., Kroes, J., & Lewin, J. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy175 · Cited by 13
Hyun, S., Lee, K. H., Han, A., & Yu, J. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0300 · Cited by 12
“Consequently, we believed that the development of tools to elucidate the mechanism(s) of regulation of phosphorylation at S10 by dimethylation at R8 would be valuable, as inhibitors of aurora B kinase represent an interesting approach to anticancer chemotherapy (Lens et al., 2010).”
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.